Azosemide

Azosemide

SCHEMBL30754398

NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 1/20 0.70
▸ PDE3A Q14432 1/20 0.70
▸ CISD1 Q9NZ45 4/20 0.58
▸ POLB P06746 1/20 0.40
▸ CA1 P00915 9/20 0.38
▸ CA2 P00918 9/20 0.38
▸ CA12 O43570 7/20 0.38
▸ CA9 Q16790 7/20 0.38
▸ CA7 P43166 4/20 0.38
▸ CA5B Q9Y2D0 4/20 0.38
▸ CA5A P35218 3/20 0.38
▸ CA6 P23280 3/20 0.38
▸ CA14 Q9ULX7 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ SLC10A1 Q14973 1/20 0.38
▸ GPR35 Q9HC97 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azosemide SCHEMBL4421865 1.00 PDE4D (0.70) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL48976 1.00 PDE4D (0.70) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL8988688 0.99 PDE4D (0.69) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL230626 0.93 PDE4D (0.62) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL231405 0.90 PDE4D (0.58) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL230300 0.89 PDE4D (0.57) PDE4DPDE3ACISD1POLBCA1
SCHEMBL11929680 0.89 PDE4D (0.55) PDE4DPDE3ACISD1POLBALDH1A1
SCHEMBL12522802 0.88 PDE4D (0.55) PDE4DPDE3ACISD1ALDH1A1PTGS2
SCHEMBL10281116 0.87 PDE4D (0.54) PDE4DPDE3ACISD1POLBALDH1A1
SCHEMBL14513929 0.87 PDE4D (0.53) PDE4DPDE3ACISD1POLBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009153-A1 BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE NEUROPRO THERAPEUTICS, INC. 2024-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240009153-A1 BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE SLC6A1, SLC6A13, SLC6A11 PDE4D 654/4885PDE3A 519/4885CISD1 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback